Next Article in Journal
Investigation into the Antihypertensive Effects of Diosmetin and Its Underlying Vascular Mechanisms Using Rat Model
Next Article in Special Issue
Identification of a Dual Inhibitor of Secreted Phospholipase A2 (GIIA sPLA2) and SARS-CoV-2 Main Protease
Previous Article in Journal
Design, Synthesis, and Antitumor Evaluation of Novel Mono-Carbonyl Curcumin Analogs in Hepatocellular Carcinoma Cell
Previous Article in Special Issue
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives
 
 
Article
Peer-Review Record

Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives

Pharmaceuticals 2022, 15(8), 949; https://doi.org/10.3390/ph15080949
by Mariola Stypik 1,2,*, Marcin Zagozda 1, Stanisław Michałek 1,2, Barbara Dymek 1, Daria Zdżalik-Bielecka 1, Maciej Dziachan 1, Nina Orłowska 1,2, Paweł Gunerka 1, Paweł Turowski 1, Joanna Hucz-Kalitowska 1, Aleksandra Stańczak 1, Paulina Stańczak 1, Krzysztof Mulewski 1, Damian Smuga 1, Filip Stefaniak 1, Lidia Gurba-Bryśkiewicz 1, Arkadiusz Leniak 1, Zbigniew Ochal 2, Mateusz Mach 1, Karolina Dzwonek 1, Monika Lamparska-Przybysz 1, Krzysztof Dubiel 1 and Maciej Wieczorek 1add Show full author list remove Hide full author list
Reviewer 1:
Reviewer 2:
Pharmaceuticals 2022, 15(8), 949; https://doi.org/10.3390/ph15080949
Submission received: 22 June 2022 / Revised: 27 July 2022 / Accepted: 28 July 2022 / Published: 30 July 2022
(This article belongs to the Special Issue Design of Enzyme Inhibitors as Potential Drugs 2022)

Round 1

Reviewer 1 Report

This submission described the development of pyrazolo-pyrimidine derivatives as PI3K-delta inhibitors. The work flow followed the order of virtual screening and evaluation on the enzymatic inhibition. The authors should improve the design concept and conduct some further experiments. I recommend a major revision.

1. What did “Part I – Indole derivatives” mean? Were there Part II or Part III?

2. The docking simulation was based on the complex containing GDC-0941, which is a pan-blocker. It was confusing that the authors designed a selective inhibitor for delta isoform based on the binding pattern of a pan-blocker. The design concept should be seriously checked and revised to construct a rational process.

3. The backbone structure also suggested that the synthesized series in this work was quite different from the selective inhibitors CDZ 173 and UCB-5857. Please include their features into the revised design concept.

4. The drawing of the structures should be standard. ACS 1996 pattern is recommended.

5. The authors should find the balance between the potency and the selectivity. In particular, in Table 4, the final choice, I think there was no obvious difference between 37 and 54. The authors should conduct some further experiments in models to check their real performance.

6. How about the toxicity?

7. In the docking simulation, the key residues were different from the reported ones. Please check it.

8. If possible, the authors should check the up-stream or down-stream nodes in the mechanism network.

9. The language use should be improved.

Author Response

Please see the attachement.

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript entitled “Design, synthesis, and development of pyrazolo[1,5-a]pyrimidine derivatives as a novel series of selective PI3Kδ inhibitors. Part I – Indole derivatives” is a wonderful study but I have one notice

The 1HNMR and 13CNMR are written in a general manner, it will be more convenient to be written in a specific manner. Which value for which proton or carbon.

 

Author Response

Please see the attachement.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors have dealt with all the comments rationally. I recommend the acceptance of the submission. A minor point: the authors should check the language use.

Back to TopTop